Search

Displaying results 3961 - 3970 of 4232 in total
  1. Drug

    Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine

    go.drugbank.com/drugs/DB15813
    Investigational

    As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

  2. Drug

    Distigmine

    go.drugbank.com/drugs/DB13694
    Investigational

    Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide.

  3. Drug

    GEM-231

    go.drugbank.com/drugs/DB05798
    Investigational

    GEM231 is a second-generation antisense oligonucleotide targeting the mRNA of the R1alpha regulatory subunit of cAMP dependent protein kinase. A monoclonal antibody combined with a toxic substance that is used treat certain types of acut...

  4. Drug

    ATG003

    go.drugbank.com/drugs/DB05069
    Investigational

    ATG003, a novel anti-angiogenic drug candidate and a formulation of mecamylamine, is currently in clinical development for neovascular age-related macular degeneration.

  5. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence. Phase IIa data for the drug show it reduced the number of incontinent episode...

  6. Drug

    Trefoil Factor 2

    go.drugbank.com/drugs/DB15750
    Experimental

    The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins. They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells,...

  7. Drug

    Recombinant human plasma gelsolin

    go.drugbank.com/drugs/DB15746
    Investigational

    Plasma gelsolin (pGSN) is a protein found in the blood of healthy individuals which scavenges compounds left over from damaged tissues.

  8. Drug

    Aducanumab

    go.drugbank.com/drugs/DB12274
    ApprovedInvestigational

    [A235668,A235720] Clinical trials showed a 23% relative difference between the experimental and placebo groups as determined by CDR; however, this is equivalent to an absolute difference of 0.4/18.

  9. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered

  10. Drug

    trans NV-04

    go.drugbank.com/drugs/DB05843
    Experimental

    trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.